問卷

TPIDB > Search Result > Clinical Trials List

Clinical Trials List

Protocol NumberBO41843
Active

2020-11-01 - 2027-12-31

Phase III

Not yet recruiting3

Recruiting3

ICD-10D05.00

Lobular carcinoma in situ of unspecified breast

ICD-10D05.01

Lobular carcinoma in situ of right breast

ICD-10D05.02

Lobular carcinoma in situ of left breast

ICD-10D05.10

Intraductal carcinoma in situ of unspecified breast

ICD-10D05.11

Intraductal carcinoma in situ of right breast

ICD-10D05.12

Intraductal carcinoma in situ of left breast

ICD-10D05.80

Other specified type of carcinoma in situ of unspecified breast

ICD-10D05.81

Other specified type of carcinoma in situ of right breast

ICD-10D05.82

Other specified type of carcinoma in situ of left breast

ICD-10D05.90

Unspecified type of carcinoma in situ of unspecified breast

ICD-10D05.91

Unspecified type of carcinoma in situ of right breast

ICD-10D05.92

Unspecified type of carcinoma in situ of left breast

ICD-9233.0

Carcinoma in situ of breast

  • Trial Applicant

  • Sponsor

  • Trial scale

    Multi-Regional Multi-Center

  • Update

    2026/04/01

Investigators and Locations

Principal Investigator YEN-SHEN LU Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator Ling-Ming Tseng Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator 張源清 Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator Yung-Chang Lin Division of Hematology & Oncology

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Not yet recruiting

Principal Investigator HWEI-CHUNG WANG Division of General Surgery

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Principal Investigator Wei-Pang Chung Division of General Internal Medicine

Co-Principal Investigator

The Actual Total Number of Participants Enrolled

0 Recruiting

Condition/Disease

Objectives

Test Drug

Active Ingredient

Dosage Form

Dosage

Endpoints

Inclution Criteria

The Estimated Number of Participants

  • Taiwan

    60 participants

  • Global

    978 participants